TAPI Technology & API Services and Sagimet Biosciences Inc. today announced entry into a license agreement.

The announcement reflects a collaboration between TAPI, a global leader in the development and manufacturing of active pharmaceutical ingredients, and Sagimet Biosciences, a clinical-stage biopharmaceutical company focused on developing novel therapeutics. This collaboration brings together complementary expertise and capabilities from both organizations.

Dr. R. Ananthanarayanan, CEO of TAPI, said:
“We are excited to announce the license agreement with Sagimet for their FDC development program, contributing TAPI’s deep experience in the development and manufacturing of APIs. APIs are essential components used in the production of medications, and TAPI has long been recognized as an industry leader in their development and manufacturing. With this collaboration with Sagimet, we are excited to contribute our innovative intellectual property and manufacturing know-how to Sagimet’s development of a product in an area of high medical need, cirrhosis of the liver, where there are currently no approved therapies.”

Further details regarding the agreement and the collaboration are provided in the full press release.
Read the full press release here: [Link]

TAPI and Antheia have announced a new strategic partnership designed to support the commercialization of Antheia’s biosynthetic key starting materials (KSMs) and active pharmaceutical ingredients (APIs). Antheia will leverage TAPI’s next-generation fermentation capabilities and manufacturing facilities in Europe to scale its pipeline and accelerate time to market for future product launches.

This collaboration combines Antheia’s innovative biosynthesis platform with TAPI’s advanced bioprocessing and manufacturing capabilities. The existing infrastructure, capacity, and quality management systems TAPI provides are well suited for Antheia’s processes, enabling efficient, reliable, and high-quality production at commercial scale. The partnership is positioned to support multiple products in Antheia’s pipeline and strengthen the long-term commercialization strategy.

With nearly a century of API manufacturing experience, TAPI offers the expertise and state-of-the-art infrastructure needed to support Antheia’s mission to transform pharmaceutical supply chains and advance essential medicines.

This collaboration reflects TAPI’s role in bringing scientific innovation and manufacturing excellence together. Through a flexible tech-transfer model and a collaborative, problem-solving approach, TAPI will support Antheia’s biosynthetic platform with advanced fermentation and enzymatic capabilities that help make these complex processes commercially viable.

To read the full announcement, click here: Antheia and TAPI Partner to Advance Global Commercialization Strategy for Critical Pharmaceutical Ingredients